Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.36 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | ATR | Q13535 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21202181 | 0.85 | ALDH1A1 (0.44) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL31105959 | 0.84 | ALDH1A1 (0.45) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL1141295 | 0.84 | RXRA (0.46) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL767423 | 0.84 | RXRA (0.43) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL767841 | 0.84 | RXRA (0.43) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL768120 | 0.84 | RXRA (0.43) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL156398 | 0.81 | RXRA (0.42) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL29416187 | 0.81 | RXRA (0.42) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL15266324 | 0.81 | RXRA (0.41) | RXRARXRBRXRGALDH1A1POLB | |
| SCHEMBL15266343 | 0.81 | RXRA (0.41) | RXRARXRBRXRGALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227480-B2 | Indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES, LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227480-B2 | Indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES, LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| CN-101460477-A | Novel indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES (JP) | 2009-06-17 | — | — | CN | disclosed |
| EP-2025676-A1 | NOVEL INDAZOLE DERIVATIVE HAVING SPIRO RING STRUCTURE IN SIDE CHAIN | Ube Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025676-A1 | NOVEL INDAZOLE DERIVATIVE HAVING SPIRO RING STRUCTURE IN SIDE CHAIN | Ube Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | CIT, ROCK1, ROCK2 | RXRA 2061/4885RXRB 1615/4885RXRG 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.